{"result": {"id": "82299c2b-2e13-42a5-aa59-5b5a6bcdecc5", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>HFrEF<|>EVENT<|>HFrEF (Heart Failure with reduced Ejection Fraction) is a type of chronic heart failure condition requiring specific medication management)\n##\n(\"entity\"<|>HFpEF<|>EVENT<|>HFpEF (Heart Failure with preserved Ejection Fraction) is a type of chronic heart failure condition requiring different management approaches)\n##\n(\"entity\"<|>心力衰竭 D 期<|>EVENT<|>心力衰竭 D 期 is an advanced stage of heart failure characterized by low blood pressure and poor organ perfusion)\n##\n(\"entity\"<|>急性心力衰竭<|>EVENT<|>急性心力衰竭 is a rapid-onset heart failure condition requiring urgent blood pressure management)\n##\n(\"relationship\"<|>HFrEF<|>ARNI<|>ARNI is a recommended treatment for HFrEF patients<|>8)\n##\n(\"relationship\"<|>HFrEF<|>ACEI<|>ACEI is a recommended treatment for HFrEF patients<|>8)\n##\n(\"relationship\"<|>HFrEF<|>ARB<|>ARB is a recommended treatment for HFrEF patients<|>8)\n##\n(\"relationship\"<|>HFrEF<|>β受体阻滞剂<|>β受体阻滞剂 is a recommended treatment for HFrEF patients<|>8)\n##\n(\"relationship\"<|>HFrEF<|>MRA<|>MRA is a recommended treatment for HFrEF patients<|>8)\n##\n(\"relationship\"<|>HFrEF<|>SGLT2i<|>SGLT2i is a recommended treatment for HFrEF patients<|>8)\n##\n(\"relationship\"<|>HFpEF<|>螺内酯<|>螺内酯 is shown to reduce hospitalization risk in HFpEF patients<|>7)\n##\n(\"relationship\"<|>HFpEF<|>沙库巴曲缬沙坦<|>沙库巴曲缬沙坦 is shown to reduce hospitalization risk in HFpEF patients<|>7)\n##\n(\"relationship\"<|>心力衰竭 D 期<|>HFrEF<|>心力衰竭 D 期 is a more advanced stage of heart failure that may include HFrEF cases<|>6)\n##\n(\"relationship\"<|>急性心力衰竭<|>硝普钠<|>硝普钠 is used to manage acute heart failure cases<|>7)\n##\n(\"relationship\"<|>急性心力衰竭<|>乌拉地尔<|>乌拉地尔 is used to manage acute heart failure cases<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558753, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 576, "prompt_tokens": 3167, "total_tokens": 3743, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3072}, "prompt_cache_hit_tokens": 3072, "prompt_cache_miss_tokens": 95}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �血压(如收缩压 ≤90mmHg) 是心力衰竭 D 期患者的临床特征之一 ,容易导致重要器官(如脑和 肾)灌注不足 ,引起器官功能障碍 ,预后比较差 。 因此 , 对于心力衰竭 D期患者 ,应维持基本或相对较高的血 压 , 以 最 大 限 度 提 高 接 受 指 南 指 导 的 药 物 治 疗 的 机会[568] 。\n　8.4.4  高血压合并慢性心力衰竭的管理    HFrEF患  者 ,首先应重视生活方式管理 ,如控制钠盐摄入、减轻  体重和增加体力活动等 。降压治疗首选有循证医学证  据支持并得到推荐的药物 ,包括 ARNI、ACEI、ARB、 β受体阻滞剂、MRA 及 SGLT2i[569-571] 。这些药物可  改善 HFrEF患者的预后 , 降低心力衰竭住院率、心血  管疾病或全因死亡率 ,治疗剂量应达到临床研究或指  南推荐的目标剂量或患者能够耐受的最大剂量 。此  外 ,大多数 HFrEF患者的治疗还包括袢利尿剂 ,也具  有良好的降压作用[569-571] 。如果经过上述药物治疗后  血压仍未达标 ,可以考虑应用氨氯地平或非洛地平等  二氢吡啶类 CCB, 因其对 HFrEF患者预后的影响是  中性的[572-573] 。不推荐使用具有负性肌力作用的非二  氢吡啶类 CCB。\n　　　HFpEF患者也应同样重视生活方式管理 。既往 心力衰竭指南对于 HFpEF患者的药物治疗推荐 , 主 要是应用袢利尿剂缓解淤血症状和/或体征 。研究显 示[574-575]  ,螺内酯和沙库巴曲缬沙坦治疗 HFpEF患者\n\n\n\n　可以显著降低心力衰竭住院风险 。在标准抗心力衰竭 治疗基础上应用 SGLT2i治疗[576-577]  , 可以显著降低 HFpEF患者心血管疾病死亡或心力衰竭住院复合终 点事件风险 。 因此 ,对于高血压合并慢性 HFpEF患 者 ,首选上述药物治疗 。如果血压不达标 ,可以联合应 用二氢吡啶类 CCB(氨氯地平或非洛地平) 或非二氢 吡啶类 CCB;不推荐使用中枢降压药 ; 除非合并前列 腺增生 ,不推荐使用 α受体阻滞剂。\n　8.4.5  高血压合并急性心力衰竭的管理    临床特点  是血压升高 , 以左心衰竭为主 ,发展迅速 。需在控制心  力衰竭的同时积极降压治疗 , 主要静脉给予袢利尿剂  和血管扩张药 ,包括硝普钠或乌拉地尔 。若病情较轻 ,  可以在 24~48h 内逐渐降压 ;病情重伴有急性肺水肿  的患者在初始 1 h 内平均动脉压的降\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ARNI<|>ORGANIZATION<|>ARNI is a type of medication recommended for HFrEF patients to improve prognosis and reduce hospitalization rates and mortality)\n##\n(\"entity\"<|>ACEI<|>ORGANIZATION<|>ACEI is a type of medication recommended for HFrEF patients to improve prognosis and reduce hospitalization rates and mortality)\n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>ARB is a type of medication recommended for HFrEF patients to improve prognosis and reduce hospitalization rates and mortality)\n##\n(\"entity\"<|>β受体阻滞剂<|>ORGANIZATION<|>β受体阻滞剂 is a type of medication recommended for HFrEF patients to improve prognosis and reduce hospitalization rates and mortality)\n##\n(\"entity\"<|>MRA<|>ORGANIZATION<|>MRA is a type of medication recommended for HFrEF patients to improve prognosis and reduce hospitalization rates and mortality)\n##\n(\"entity\"<|>SGLT2i<|>ORGANIZATION<|>SGLT2i is a type of medication recommended for HFrEF patients to improve prognosis and reduce hospitalization rates and mortality)\n##\n(\"entity\"<|>螺内酯<|>ORGANIZATION<|>螺内酯 is a medication shown to reduce hospitalization risk in HFpEF patients)\n##\n(\"entity\"<|>沙库巴曲缬沙坦<|>ORGANIZATION<|>沙库巴曲缬沙坦 is a medication shown to reduce hospitalization risk in HFpEF patients)\n##\n(\"entity\"<|>硝普钠<|>ORGANIZATION<|>硝普钠 is a vasodilator used in the management of acute heart failure with elevated blood pressure)\n##\n(\"entity\"<|>乌拉地尔<|>ORGANIZATION<|>乌拉地尔 is a vasodilator used in the management of acute heart failure with elevated blood pressure)\n##\n(\"relationship\"<|>ARNI<|>ACEI<|>Both ARNI and ACEI are recommended medications for HFrEF patients<|>5)\n##\n(\"relationship\"<|>ARB<|>ACEI<|>Both ARB and ACEI are recommended medications for HFrEF patients<|>5)\n##\n(\"relationship\"<|>β受体阻滞剂<|>MRA<|>Both β受体阻滞剂 and MRA are recommended medications for HFrEF patients<|>5)\n##\n(\"relationship\"<|>SGLT2i<|>MRA<|>Both SGLT2i and MRA are recommended medications for HFrEF patients<|>5)\n##\n(\"relationship\"<|>螺内酯<|>沙库巴曲缬沙坦<|>Both 螺内酯 and 沙库巴曲缬沙坦 are medications shown to reduce hospitalization risk in HFpEF patients<|>5)\n##\n(\"relationship\"<|>硝普钠<|>乌拉地尔<|>Both 硝普钠 and 乌拉地尔 are vasodilators used in the management of acute heart failure with elevated blood pressure<|>5)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_bc1568e85d0f24ec006697b4c52ad38edcc5bd1a5ccdf437802455b807503660_v2"}